Literature DB >> 28050011

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer.

Rodrigo Dienstmann1,2, Louis Vermeulen3, Justin Guinney2, Scott Kopetz4, Sabine Tejpar5, Josep Tabernero1.   

Abstract

Critical driver genomic events in colorectal cancer have been shown to affect the response to targeted agents that were initially developed under the 'one gene, one drug' paradigm of precision medicine. Our current knowledge of the complexity of the cancer genome, clonal evolution patterns under treatment pressure and pharmacodynamic effects of target inhibition support the transition from a one gene, one drug approach to a 'multi-gene, multi-drug' model when making therapeutic decisions. Better characterization of the transcriptomic subtypes of colorectal cancer, encompassing tumour, stromal and immune components, has revealed convergent pathway dependencies that mandate a 'multi-molecular' perspective for the development of therapies to treat this disease.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28050011     DOI： 10.1038/nrc.2016.126

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  141 in total

1.  The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies.

Authors:  Claudia Esposito; Anna Maria Rachiglio; Maria Libera La Porta; Alessandra Sacco; Cristin Roma; Alessia Iannaccone; Fabiana Tatangelo; Laura Forgione; Raffaella Pasquale; Americo Barbaro; Gerardo Botti; Fortunato Ciardiello; Nicola Normanno
Journal:  Cancer Biol Ther       Date:  2013-09-23       Impact factor: 4.742

2.  Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.

Authors:  Clara Montagut; Alba Dalmases; Beatriz Bellosillo; Marta Crespo; Silvia Pairet; Mar Iglesias; Marta Salido; Manuel Gallen; Scot Marsters; Siao Ping Tsai; André Minoche; Somasekar Seshagiri; Seshagiri Somasekar; Sergi Serrano; Heinz Himmelbauer; Joaquim Bellmunt; Ana Rovira; Jeff Settleman; Francesc Bosch; Joan Albanell
Journal:  Nat Med       Date:  2012-01-22       Impact factor: 53.440

3.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Authors:  Ryan B Corcoran; Hiromichi Ebi; Alexa B Turke; Erin M Coffee; Michiya Nishino; Alexandria P Cogdill; Ronald D Brown; Patricia Della Pelle; Dora Dias-Santagata; Kenneth E Hung; Keith T Flaherty; Adriano Piris; Jennifer A Wargo; Jeffrey Settleman; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2012-01-16       Impact factor: 39.397

4.  IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.

Authors:  Eugenia R Zanella; Francesco Galimi; Francesco Sassi; Giorgia Migliardi; Francesca Cottino; Simonetta M Leto; Barbara Lupo; Jessica Erriquez; Claudio Isella; Paolo M Comoglio; Enzo Medico; Sabine Tejpar; Eva Budinská; Livio Trusolino; Andrea Bertotti
Journal:  Sci Transl Med       Date:  2015-01-28       Impact factor: 17.956

5.  Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial.

Authors:  E Élez; I Kocáková; T Höhler; U M Martens; C Bokemeyer; E Van Cutsem; B Melichar; M Smakal; T Csőszi; E Topuzov; R Orlova; S Tjulandin; F Rivera; J Straub; R Bruns; S Quaratino; J Tabernero
Journal:  Ann Oncol       Date:  2014-10-15       Impact factor: 32.976

6.  Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.

Authors:  Sabrina Arena; Beatriz Bellosillo; Giulia Siravegna; Alejandro Martínez; Israel Cañadas; Luca Lazzari; Noelia Ferruz; Mariangela Russo; Sandra Misale; Iria González; Mar Iglesias; Elena Gavilan; Giorgio Corti; Sebastijan Hobor; Giovanni Crisafulli; Marta Salido; Juan Sánchez; Alba Dalmases; Joaquim Bellmunt; Gianni De Fabritiis; Ana Rovira; Federica Di Nicolantonio; Joan Albanell; Alberto Bardelli; Clara Montagut
Journal:  Clin Cancer Res       Date:  2015-01-26       Impact factor: 12.531

7.  Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells.

Authors:  Cristina Oliveras-Ferraros; Alejandro Vazquez-Martin; Sílvia Cufí; Bernardo Queralt; Luciana Báez; Raquel Guardeño; Xavier Hernández-Yagüe; Begoña Martin-Castillo; Joan Brunet; Javier A Menendez
Journal:  J Cell Biochem       Date:  2011-01       Impact factor: 4.429

8.  Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior.

Authors:  Beatriz Perez-Villamil; Alejandro Romera-Lopez; Susana Hernandez-Prieto; Guillermo Lopez-Campos; Antonio Calles; Jose-Antonio Lopez-Asenjo; Julian Sanz-Ortega; Cristina Fernandez-Perez; Javier Sastre; Rosario Alfonso; Trinidad Caldes; Fernando Martin-Sanchez; Eduardo Diaz-Rubio
Journal:  BMC Cancer       Date:  2012-06-19       Impact factor: 4.430

9.  Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.

Authors:  Sandra Misale; Ivana Bozic; Jingshan Tong; Ashley Peraza-Penton; Alice Lallo; Federica Baldi; Kevin H Lin; Mauro Truini; Livio Trusolino; Andrea Bertotti; Federica Di Nicolantonio; Martin A Nowak; Lin Zhang; Kris C Wood; Alberto Bardelli
Journal:  Nat Commun       Date:  2015-09-22       Impact factor: 14.919

10.  Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing.

Authors:  Sumitra Mohan; Ellen Heitzer; Peter Ulz; Ingrid Lafer; Sigurd Lax; Martina Auer; Martin Pichler; Armin Gerger; Florian Eisner; Gerald Hoefler; Thomas Bauernhofer; Jochen B Geigl; Michael R Speicher
Journal:  PLoS Genet       Date:  2014-03-27       Impact factor: 6.020
View more
  264 in total

1.  Tumor SQSTM1 (p62) expression and T cells in colorectal cancer.

Authors:  Keisuke Kosumi; Yohei Masugi; Juhong Yang; Zhi Rong Qian; Sun A Kim; Wanwan Li; Yan Shi; Annacarolina da Silva; Tsuyoshi Hamada; Li Liu; Mancang Gu; Tyler S Twombly; Yin Cao; David A Barbie; Katsuhiko Nosho; Hideo Baba; Wendy S Garrett; Jeffery A Meyerhardt; Edward L Giovannucci; Andrew T Chan; Charles S Fuchs; Shuji Ogino; Reiko Nishihara
Journal:  Oncoimmunology       Date:  2017-01-31       Impact factor: 8.110

2.  Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas.

Authors:  Yang Liu; Nilay S Sethi; Toshinori Hinoue; Barbara G Schneider; Andrew D Cherniack; Francisco Sanchez-Vega; Jose A Seoane; Farshad Farshidfar; Reanne Bowlby; Mirazul Islam; Jaegil Kim; Walid Chatila; Rehan Akbani; Rupa S Kanchi; Charles S Rabkin; Joseph E Willis; Kenneth K Wang; Shannon J McCall; Lopa Mishra; Akinyemi I Ojesina; Susan Bullman; Chandra Sekhar Pedamallu; Alexander J Lazar; Ryo Sakai; Vésteinn Thorsson; Adam J Bass; Peter W Laird
Journal:  Cancer Cell       Date:  2018-04-02       Impact factor: 31.743

3.  Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models.

Authors:  Janneke F Linnekamp; Sander R van Hooff; Pramudita R Prasetyanti; Raju Kandimalla; Joyce Y Buikhuisen; Evelyn Fessler; Prashanthi Ramesh; Kelly A S T Lee; Grehor G W Bochove; Johan H de Jong; Kate Cameron; Ronald van Leersum; Hans M Rodermond; Marek Franitza; Peter Nürnberg; Laura R Mangiapane; Xin Wang; Hans Clevers; Louis Vermeulen; Giorgio Stassi; Jan Paul Medema
Journal:  Cell Death Differ       Date:  2018-01-05       Impact factor: 15.828

4.  Intestinal PPARα Protects Against Colon Carcinogenesis via Regulation of Methyltransferases DNMT1 and PRMT6.

Authors:  Yuhong Luo; Cen Xie; Chad N Brocker; Jie Fan; Xuan Wu; Lijin Feng; Qiong Wang; Jie Zhao; Dasheng Lu; Mayank Tandon; Maggie Cam; Kristopher W Krausz; Weiwei Liu; Frank J Gonzalez
Journal:  Gastroenterology       Date:  2019-05-30       Impact factor: 22.682

5.  Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer.

Authors:  Rodrigo Dienstmann; Louis Vermeulen; Justin Guinney; Scott Kopetz; Sabine Tejpar; Josep Tabernero
Journal:  Nat Rev Cancer       Date:  2017-03-23       Impact factor: 60.716

6.  NSAIDs and Colorectal Cancer Phenotypes: What Now?

Authors:  Elizabeth L Barry; Veronika Fedirko; John A Baron
Journal:  J Natl Cancer Inst       Date:  2019-05-01       Impact factor: 13.506

Review 7.  Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome-driven neoplasms.

Authors:  Tsuyoshi Hamada; Jonathan A Nowak; Danny A Milner; Mingyang Song; Shuji Ogino
Journal:  J Pathol       Date:  2019-02-20       Impact factor: 7.996

8.  DNA hypermethylation as a predictor of extramural vascular invasion (EMVI) in rectal cancer.

Authors:  Rory F Kokelaar; Huw G Jones; Jeremy Williamson; Namor Williams; A Paul Griffiths; John Beynon; Gareth J Jenkins; Dean A Harris
Journal:  Cancer Biol Ther       Date:  2018-01-19       Impact factor: 4.742

9.  In Defense of Flossing: Part II-Can We Agree It's Premature to Claim Flossing Is Ineffective to Help Prevent Periodontal Diseases?

Authors:  Lance T Vernon; Andre Paes B Da Silva; Jason D Seacat
Journal:  J Evid Based Dent Pract       Date:  2017-06-27       Impact factor: 5.267

10.  Identification of an immune overdrive high-risk subpopulation with aberrant expression of FOXP3 and CTLA4 in colorectal cancer.

Authors:  Kaisa Cui; Surui Yao; Han Zhang; Mingyue Zhou; Bingxin Liu; Yulin Cao; Bojian Fei; Shenglin Huang; Zhaohui Huang
Journal:  Oncogene       Date:  2021-02-24       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.